	US 12,421,301 B2
	Anti-influenza neuraminidase monoclonal antibodies and uses thereof
James J. Kobie, Rochester, NY (US); Luis Martinez-Sobrido, Rochester, NY (US); Michael Piepenbrink, Rochester, NY (US); and Aitor Nogales, Rochester, NY (US)
Assigned to University of Rochester, Rochester, NY (US)
Filed by University of Rochester, Rochester, NY (US)
Filed on Mar. 5, 2024, as Appl. No. 18/596,217.
Application 18/596,217 is a division of application No. 17/049,400, granted, now 11,958,895, previously published as PCT/US2019/030383, filed on May 2, 2019.
Claims priority of provisional application 62/666,180, filed on May 3, 2018.
Prior Publication US 2024/0254205 A1, Aug. 1, 2024
Int. Cl. C07K 16/00 (2006.01); A61K 39/00 (2006.01); A61K 39/42 (2006.01); A61P 31/16 (2006.01); C07K 16/10 (2006.01)

CPC C07K 16/1018 (2013.01) [A61K 39/42 (2013.01); A61P 31/16 (2018.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/52 (2013.01); C07K 2317/76 (2013.01)]

16 Claims

1. An isolated antibody or antigen-binding fragment thereof that specifically binds to a neuraminidase of influenza virus, comprising:

(i) a heavy chain variable region that comprises HCDR1, HCDR2, and HCDR3 comprising the respective sequences of SEQ ID NOs: 43-45, and

(ii) a light chain variable region that comprises LCDR1, LCDR2, and LCDR3 comprising the respective sequences of SEQ ID NOs: 46-48.